Total Payments
$246,136
2024 Payments
$70,218
Companies
27
Transactions
218
Medicare Patients
8,143
Medicare Billing
$1.0M
Payment Breakdown by Category
Consulting$163,036 (66.2%)
Research$51,788 (21.0%)
Other$19,908 (8.1%)
Food & Beverage$5,742 (2.3%)
Travel$5,642 (2.3%)
Gifts$19.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $163,036 | 64 | 66.2% |
| Unspecified | $51,788 | 50 | 21.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,908 | 11 | 7.3% |
| Food and Beverage | $5,742 | 69 | 2.3% |
| Travel and Lodging | $5,642 | 21 | 2.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,500 | 1 | 0.6% |
| Honoraria | $500.00 | 1 | 0.2% |
| Gift | $19.40 | 1 | 0.0% |
Payments by Type
General
$194,348
168 transactions
Research
$51,788
50 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $89,909 | 66 | $0 (2024) |
| Alcon Vision LLC | $33,574 | 27 | $0 (2023) |
| Genentech, Inc. | $29,737 | 21 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $25,656 | 15 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $21,146 | 11 | $0 (2024) |
| Topcon Healthcare, Inc. | $15,000 | 4 | $0 (2024) |
| Genentech USA, Inc. | $8,607 | 20 | $0 (2024) |
| Allergan Inc. | $5,846 | 7 | $0 (2018) |
| Apellis Pharmaceuticals, Inc. | $4,929 | 10 | $0 (2022) |
| Carl Zeiss Meditec, Inc. | $4,570 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,218 | 64 | F. Hoffmann-La Roche AG ($37,136) |
| 2023 | $46,057 | 46 | F. Hoffmann-La Roche AG ($19,397) |
| 2022 | $42,882 | 44 | Alcon Vision LLC ($12,727) |
| 2021 | $40,506 | 19 | Genentech, Inc. ($12,450) |
| 2020 | $16,774 | 8 | Genentech, Inc. ($7,275) |
| 2019 | $2,684 | 9 | F. Hoffmann-La Roche AG ($2,128) |
| 2018 | $15,802 | 17 | Allergan Inc. ($5,816) |
| 2017 | $11,213 | 11 | F. Hoffmann-La Roche AG ($9,412) |
All Payment Transactions
218 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,362.50 | Research |
| Study: How Intravitreal Anti-Vascular Endothelial Growth Factor Initial Dosing Impacts Patient Outcomes in Diabetic Macular Edema | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $501.00 | Research |
| Study: Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in Diabetic Macular Edema (DME) | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $296.25 | Research |
| Study: 2-Year Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Faricimab in the United States: The FARETINA Study | ||||||
| 12/09/2024 | Topcon Healthcare, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 11/11/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,975.00 | General |
| 11/02/2024 | Topcon Healthcare, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 10/17/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $203.51 | General |
| 10/15/2024 | Topcon Healthcare, Inc. | — | Consulting Fee | Cash or cash equivalent | $8,000.00 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,040.75 | Research |
| Study: Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in Diabetic Macular Edema (DME) | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,171.25 | Research |
| Study: Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: The FARETINA-AMD study | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,171.25 | Research |
| Study: Real-World Clinical and Anatomical Outcomes in Patients with Diabetic Macular Edema Treated with Faricimab: the FARETINA-DME Study | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,041.11 | Research |
| Study: 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Neovascular Age-Related Macular Degeneration: FARETINA-AMD | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $937.00 | Research |
| Study: Real-World Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From FARETINA-nAMD and FARWIDE-nAMD Studies | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $937.00 | Research |
| Study: Real-World Effectiveness of Faricimab in Patients With Diabetic Macular Edema: 12-Month Outcomes From FARETINA-DME and FARWIDE-DME Studies | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $742.22 | Research |
| Study: 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $668.00 | Research |
| Study: Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in Diabetic Macular Edema (DME) | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $480.00 | Research |
| Study: Real-World Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From FARETINA-nAMD and FARWIDE-nAMD Studies | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $480.00 | Research |
| Study: Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in Diabetic Macular Edema (DME) | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $421.25 | Research |
| Study: Two-Year Real-World Clinical Outcomes Update With Faricimab in Patients With Neovascular Age-Related Macular Degeneration in the USA: The FARETINA-AMD Study | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $421.25 | Research |
| Study: 12-Month Real-World Clinical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab in the USA: The FARETINA-DME Study | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $374.44 | Research |
| Study: 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $374.44 | Research |
| Study: 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Neovascular Age-Related Macular Degeneration: FARETINA-AMD | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $337.00 | Research |
| Study: Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in Diabetic Macular Edema (DME) | ||||||
| 09/18/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,747.50 | General |
| 09/13/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $116.08 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Real-World Clinical and Anatomical Outcomes in Patients with Diabetic Macular Edema Treated with Faricimab: the FARETINA-DME Study | F. Hoffmann-La Roche AG | $6,508 | 6 |
| Real-World Clinical and Anatomical Outcomes in Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab: the FARETINA-AMD Study | F. Hoffmann-La Roche AG | $4,696 | 2 |
| Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in Diabetic Macular Edema (DME) | F. Hoffmann-La Roche AG | $4,448 | 6 |
| IRIS: The Intelligent Retinal Imaging System | F. Hoffmann-La Roche AG | $4,352 | 3 |
| LONG-TERM EXPERIENCE WITH INTRAVITREAL ANTI-VEGF IN PATIENTS WITH NAMD ANALYSIS OF INTELLIGENT RESEARCH IN SIGHT IRIS REGISTRY DATABASE | F. Hoffmann-La Roche AG | $3,930 | 2 |
| Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: The FARETINA-AMD study | F. Hoffmann-La Roche AG | $3,347 | 4 |
| How Intravitreal Anti-Vascular Endothelial Growth Factor Initial Dosing Impacts Patient Outcomes in Diabetic Macular Edema | F. Hoffmann-La Roche AG | $3,135 | 2 |
| How Intravitreal Anti-Vascular Endothelial Growth Factor Loading Doses Impact Patient Outcomes in Diabetic Macular Edema | F. Hoffmann-La Roche AG | $2,805 | 1 |
| Early Treatment Patterns and Outcomes in Patients with Diabetic Macular Edema Treated with Faricimab: the FARETINA-DME Study | F. Hoffmann-La Roche AG | $2,104 | 1 |
| Early Treatment Patterns and Outcomes in Patients with Neovascular Age-Related Macular Degeneration Initiating Faricimab: the FARETINA-AMD Study | F. Hoffmann-La Roche AG | $2,104 | 1 |
| Comparative Efficacy of Faricimab for the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis | F. Hoffmann-La Roche AG | $2,047 | 2 |
| Real-World Effectiveness of Faricimab in Patients With Diabetic Macular Edema: 12-Month Outcomes From FARETINA-DME and FARWIDE-DME Studies | F. Hoffmann-La Roche AG | $1,417 | 2 |
| Real-World Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From FARETINA-nAMD and FARWIDE-nAMD Studies | F. Hoffmann-La Roche AG | $1,417 | 2 |
| 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Neovascular Age-Related Macular Degeneration: FARETINA-AMD | F. Hoffmann-La Roche AG | $1,416 | 2 |
| 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study | F. Hoffmann-La Roche AG | $1,117 | 2 |
| UK Faricimab Real-World Evidence (UK FARWIDE) Study: Evaluation of Faricimab uptake patient characteristics treatment patterns and visual acuity outcomes over time | F. Hoffmann-La Roche AG | $1,113 | 1 |
| Early Treatment Patterns and Outcomes in Diabetic Macular Edema Patients Initiating Faricimab in the US and UK | F. Hoffmann-La Roche AG | $1,096 | 1 |
| Early Treatment Patterns and Outcomes in Neovascular Age-Related Macular Degeneration (nAMD) Patients Initiating Faricimab in the US and UK | F. Hoffmann-La Roche AG | $1,096 | 1 |
| FARETINA-DME-six-month treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab: an IRIS (tm) Registry analysis | F. Hoffmann-La Roche AG | $1,096 | 1 |
| IRIS NAMD TREATMENT PATTERNS STUDY | F. Hoffmann-La Roche AG | $508.67 | 1 |
| Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD) Treated With Faricimab in the United States: The FARETINA Study | F. Hoffmann-La Roche AG | $425.91 | 1 |
| 12-Month Real-World Clinical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab in the USA: The FARETINA-DME Study | F. Hoffmann-La Roche AG | $421.25 | 1 |
| Two-Year Real-World Clinical Outcomes Update With Faricimab in Patients With Neovascular Age-Related Macular Degeneration in the USA: The FARETINA-AMD Study | F. Hoffmann-La Roche AG | $421.25 | 1 |
| FARETINA-DME real-world injection frequency, visual acuity and anatomical outcomes ?12-month follow up | F. Hoffmann-La Roche AG | $359.00 | 1 |
| 2-Year Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Faricimab in the United States: The FARETINA Study | F. Hoffmann-La Roche AG | $296.25 | 1 |
| Trition OCT-A Pre-Study Pilot 1 | TOPCON HEALTHCARE SOLUTIONS, INC. | $105.02 | 1 |
| Trition OCT-A Pre-Study Pilot 1 | TOPCON MEDICAL SYSTEMS, INC. | $6.95 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 2,176 | 4,902 | $1.9M | $287,815 |
| 2022 | 8 | 2,080 | 4,681 | $1.5M | $255,590 |
| 2021 | 11 | 2,138 | 4,649 | $1.4M | $259,464 |
| 2020 | 11 | 1,749 | 4,055 | $1.3M | $216,055 |
Total Patients
8,143
Total Services
18,287
Medicare Billing
$1.0M
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 874 | 1,390 | $163,100 | $115,041 | 70.5% |
| 67028 | Injection of drug into eye | Office | 2023 | 206 | 1,185 | $1.5M | $113,260 | 7.5% |
| 92134 | Imaging of retina | Office | 2023 | 870 | 2,089 | $159,260 | $47,004 | 29.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 92 | 92 | $16,744 | $9,688 | 57.9% |
| 92228 | Imaging of retina with remote review by physician | Office | 2023 | 48 | 48 | $4,526 | $632.38 | 14.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 12 | $5,736 | $570.60 | 9.9% |
| 92250 | Photography of the retina | Office | 2023 | 20 | 25 | $6,628 | $451.72 | 6.8% |
| 92228 | Imaging of retina with remote review by physician | Facility | 2023 | 27 | 28 | $3,148 | $416.61 | 13.2% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 13 | 14 | $1,926 | $400.40 | 20.8% |
| 92134 | Imaging of retina | Facility | 2023 | 15 | 19 | $5,700 | $350.10 | 6.1% |
| 67028 | Injection of drug into eye | Office | 2022 | 194 | 1,165 | $1.2M | $102,139 | 8.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 826 | 1,251 | $147,828 | $98,002 | 66.3% |
| 92134 | Imaging of retina | Office | 2022 | 804 | 2,001 | $123,909 | $43,628 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 79 | 79 | $14,978 | $8,307 | 55.5% |
| 92228 | Imaging of retina with remote review by physician | Office | 2022 | 61 | 61 | $8,050 | $880.35 | 10.9% |
| 92228 | Imaging of retina with remote review by physician | Facility | 2022 | 55 | 55 | $5,005 | $859.15 | 17.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 13 | $6,076 | $658.02 | 10.8% |
| 92250 | Photography of the retina | Office | 2022 | 23 | 25 | $5,684 | $430.82 | 7.6% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 14 | 15 | $2,235 | $353.06 | 15.8% |
| 92134 | Imaging of retina | Facility | 2022 | 12 | 16 | $4,716 | $331.88 | 7.0% |
| 67028 | Injection of drug into eye | Office | 2021 | 188 | 1,144 | $1.1M | $104,855 | 9.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 735 | 1,069 | $123,328 | $89,726 | 72.8% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 800 | 2,010 | $118,590 | $44,635 | 37.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 99 | 99 | $18,018 | $11,384 | 63.2% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 131 | 133 | $31,255 | $4,352 | 13.9% |
About Dr. Theodore Leng, MD
Dr. Theodore Leng, MD is a Ophthalmology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1144438987.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Theodore Leng, MD has received a total of $246,136 in payments from pharmaceutical and medical device companies, with $70,218 received in 2024. These payments were reported across 218 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($163,036).
As a Medicare-enrolled provider, Leng has provided services to 8,143 Medicare beneficiaries, totaling 18,287 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Stanford, CA
- Active Since 05/17/2007
- Last Updated 03/21/2024
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1144438987
Products in Payments
- Lucentis (Biological) $28,205
- EYLEA (Biological) $20,941
- Constellation (Device) $17,873
- Luxor (Device) $9,906
- EYLEA HD (Biological) $5,072
- CIRRUS HD-OCT (Device) $4,500
- VABYSMO (Drug) $3,687
- NGENUITY (Device) $2,116
- YUTIQ (Drug) $1,713
- Non-Covered Product (Drug) $1,500
- Izervay (Drug) $341.49
- Vabysmo (Drug) $298.63
- ILUVIEN (Drug) $233.07
- OXERVATE (Drug) $153.12
- SUSVIMO (Drug) $149.17
- Iluvien (Drug) $125.00
- Tecnis IOL (Device) $119.48
- ACTHAR (Biological) $115.24
- OCT-TRITON-A (Device) $105.02
- Susvimo (Drug) $99.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Stanford
Kuldev Singh, Md, MD
Ophthalmology — Payments: $1.9M
Ophthalmology $1.9M
Ehsan Rahimy, Md, MD
Ophthalmology — Payments: $1.3M
Ophthalmology $1.3M
Quan Nguyen, Md, MD
Ophthalmology — Payments: $999,300
Ophthalmology $999,300
Diana Do, Md, MD
Ophthalmology — Payments: $383,793
Ophthalmology $383,793
Robert Chang, Md, MD
Ophthalmology — Payments: $107,945
Ophthalmology $107,945
Ramsudha Narala, Md, MD
Ophthalmology — Payments: $96,310
Ophthalmology $96,310